We are live on ! Find out more
IBER.U

Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant

Delisted

IBER.U was delisted on the 1st of March, 2023.

27 hedge funds and large institutions have $49.6M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

5% less capital invested

Capital invested by funds: $52.4M → $49.6M (-$2.81M)

21% less funds holding

Funds holding: 3427 (-7)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
27
Holders Change
-7
Holders Change %
-20.59%
% of All Funds
0.47%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
3
Reduced
4
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
26
Condor Capital Management
New Jersey
$24K
Walleye Capital
27
Walleye Capital
New York
$1.2K
CCA
28
Castle Creek Arbitrage
Colorado
-$2.54M -253,446 Closed
Citadel Advisors
29
Citadel Advisors
Florida
-$2.29M -227,788 Closed
SSA
30
Schonfeld Strategic Advisors
New York
-$1.36M -135,445 Closed
BCM
31
Basso Capital Management
Connecticut
-$1.36M -135,404 Closed
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
-$559K -55,587 Closed
CCM
33
CAAS Capital Management
New York
-$251K -25,000 Closed
CI Investments Inc
34
CI Investments Inc
Ontario, Canada
-$51K -5,100 Closed

IBER.U Hedge Fund Activity: Q3 2021 in Review

27 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q3 2021, worth a combined $49.6M — down 5.4% from $52.4M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of IBER.U and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Omni Partners US, adding an estimated $186K. The largest seller was Castle Creek Arbitrage, exiting entirely with an estimated $2.54M sold.

  • 27 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q3 2021, down from 34 in Q2 2021.
  • Funds reported $49.6M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q3 2021, down 5.4% quarter-over-quarter.
  • 1 fund opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q3 2021 and 7 closed out, a net change of -6 holders.
  • The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q3 2021 was Omni Partners US, an estimated $186K added.
  • The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q3 2021 was Castle Creek Arbitrage, an estimated $2.54M sold.

Based on aggregated 13F filings for Q3 2021.